Capital International Ltd. CA Has $2.89 Million Holdings in AstraZeneca PLC (NASDAQ:AZN)

Capital International Ltd. CA cut its position in AstraZeneca PLC (NASDAQ:AZNFree Report) by 6.7% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 42,861 shares of the company’s stock after selling 3,062 shares during the period. Capital International Ltd. CA’s holdings in AstraZeneca were worth $2,887,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in AZN. Wellington Management Group LLP raised its stake in shares of AstraZeneca by 0.7% in the third quarter. Wellington Management Group LLP now owns 49,492,814 shares of the company’s stock worth $3,351,653,000 after acquiring an additional 358,399 shares during the last quarter. Capital International Investors raised its stake in shares of AstraZeneca by 0.5% in the fourth quarter. Capital International Investors now owns 34,782,762 shares of the company’s stock worth $2,342,367,000 after acquiring an additional 164,183 shares during the last quarter. Sanders Capital LLC raised its stake in shares of AstraZeneca by 39.0% in the fourth quarter. Sanders Capital LLC now owns 14,684,066 shares of the company’s stock worth $988,972,000 after acquiring an additional 4,122,965 shares during the last quarter. CIBC Private Wealth Group LLC raised its stake in shares of AstraZeneca by 9.3% in the fourth quarter. CIBC Private Wealth Group LLC now owns 10,424,914 shares of the company’s stock worth $708,617,000 after acquiring an additional 889,178 shares during the last quarter. Finally, Fisher Asset Management LLC raised its stake in shares of AstraZeneca by 2.5% in the fourth quarter. Fisher Asset Management LLC now owns 9,404,023 shares of the company’s stock worth $633,361,000 after acquiring an additional 233,015 shares during the last quarter. 20.35% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the stock. BMO Capital Markets boosted their target price on shares of AstraZeneca from $80.00 to $82.00 and gave the stock an “outperform” rating in a research note on Friday, April 26th. Argus boosted their price target on shares of AstraZeneca from $80.00 to $85.00 and gave the stock a “buy” rating in a research note on Thursday, May 30th. Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Tuesday, April 16th. Finally, The Goldman Sachs Group initiated coverage on shares of AstraZeneca in a research note on Thursday, May 30th. They set a “buy” rating and a $97.00 price target for the company. Three analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, AstraZeneca has an average rating of “Moderate Buy” and an average target price of $88.00.

View Our Latest Analysis on AstraZeneca

AstraZeneca Trading Up 0.4 %

NASDAQ:AZN traded up $0.34 during trading hours on Wednesday, hitting $80.36. The stock had a trading volume of 3,078,381 shares, compared to its average volume of 5,922,683. AstraZeneca PLC has a one year low of $60.47 and a one year high of $80.67. The company has a debt-to-equity ratio of 0.73, a quick ratio of 0.70 and a current ratio of 0.89. The company has a market cap of $249.15 billion, a price-to-earnings ratio of 39.23, a P/E/G ratio of 1.41 and a beta of 0.48. The business’s 50 day moving average is $73.46 and its 200-day moving average is $68.49.

AstraZeneca (NASDAQ:AZNGet Free Report) last issued its earnings results on Thursday, April 25th. The company reported $1.03 EPS for the quarter, beating the consensus estimate of $0.95 by $0.08. AstraZeneca had a net margin of 13.30% and a return on equity of 30.42%. The firm had revenue of $12.68 billion during the quarter, compared to the consensus estimate of $11.92 billion. Sell-side analysts anticipate that AstraZeneca PLC will post 4.04 EPS for the current fiscal year.

AstraZeneca Profile

(Free Report)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

Featured Articles

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZNFree Report).

Institutional Ownership by Quarter for AstraZeneca (NASDAQ:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.